Follow Us on StockTwits

Intercept Pharmaceuticals Beats on Earnings and Revenue

Posted by on May 4, 2017 6:46 AM
Tags: , , , , ,
Categories: Stocks

May 04, 2017: Intercept Pharmaceuticals reports Q1 EPS of -$3.61 versus the -$4.27 estimate. Revenue also beat coming in at $21 million versus the $15.9 million estimate. As of March 31, 2017, Intercept had cash, cash equivalents and investment securities available for sale of approximately $608 million, compared to $689.4 million as of December 31, 2016.

The CEO said that they completed enrollment of Phase 3 REGENERATE trial interim analysis cohort: data expected in 1H 2019.

Anticipated 2017 Milestones:

PBC Program
Ongoing U.S. Ocaliva launch
Launch Ocaliva in key European markets and seek regulatory approval in other target international markets
Continue enrollment of Phase 4 COBALT trial evaluating the effect of Ocaliva on clinical outcomes in PBC

NASH Program
Report CONTROL top-line results in mid-2017
Initiate Phase 3 trial in NASH patients with cirrhosis during 2H 2017

Report AESOP top-line results in mid-2017
Initiate Phase 2 trial for INT-767, a dual FXR/TGR5 agonist, in NASH patients with fibrosis during 2H 2017

December 28, 2016: Hearing takeover rumors about biotechnology firm Intercept Pharmaceuticals. The rumor is that Novartis could be a potential acquirer. Can not find the source of the rumors. StreetInsider asked an Intercept Pharmaceuticals spokesperson about the rumor and the company said it will not comment on M&A speculation.

Intercept Pharmaceuticals Stock Chart

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases.


Follow me

Lance Jepsen

For ethical purposes, I try not to hold any position in any stock I profile on unless specifically stated in the article. Owner of Seasoned entrepreneur, investor, and writer. I love God, family, country, stock trading, economics, and helping people learn how to trade.
Follow me